[ad_1]
BAN2401 Clinical Phase 2, Blood Pressure, Liver Function and Alzheimer's Disease
International Conference of the Alzheimer's Association 2018 (AAIC 2018)
Among them, the guidelines for clinical evaluation of dementia highlighting the importance of early diagnosis, and the results of clinical phase 2 of BAN2401, which is the hope of dementia treatment, are representative.
Guide to Clinical Evaluation of Dementia with Early Diagnosis
The International Association of Alzheimer's Disease (ADDA) has established guidelines for early diagnosis of Alzheimer's disease that highlight the importance of early diagnosis of Alzheimer's disease.
This is a measure highlighting the importance of preventive care because of the high costs and risks that will arise if Alzheimer's disease is not not managed at an early stage.
In fact, early Alzheimer's disease is an indication that you should take a variety of steps to diagnose your illness if you think that your patients or caregivers have problems with their cognitive function because they can not diagnose correctly in the hospital.
The contents are as follows: ▲ Patient with cognitive function and behavioral change After performing various tests, medical personnel consider themselves to be an expert ▲ To diagnose cognitive behavior syndrome, consider individual risk factors ▲ Communicate with medical staff, patients and caregivers during the examination process.
BAN2401 rate of symptom progression delayed by 30% compared to control group
The guide published this time contains only basic contents, 19659002] BAN 2401, a dementia drug jointly developed by Zai and Biogen in the Phase II clinical trial, a toxic protein called "beta-amyloid" in brain neurons, considered a cause of dementia,
Clinical trials have shown that training of amyloid beta plaques,
Clinical trials have shown that the group with the highest dose of the highest dose has a higher amyloid content than the placebo group Decreased symptoms and decreased decline cognitive. In particular, approximately 81% of amyloid levels in this group were significantly decreased from benign to negative, and the rate of progression of dementia symptoms was 30% slower than in the control group.
Lowering Blood Pressure to 120mmHg
Dr. Jeff Williamson, an elderly medical specialist at the Wake Forest Medical Center in North Carolina, United States, unveiled the results of a clinical trial of two years out of 9,361 hypertensive patients over 50 years old.
One group had a maximum blood pressure of 140mmHg and one group B had three medications for hypertension and a maximum blood pressure of 120mmHg.
Group A had an average systolic blood pressure of 121mmHg, group B Maintenance of 135 mmHg. Two years later, cognitive function tests revealed that the incidence of mild cognitive impairment was 19% lower for group A than for group B.
Degradation of liver function may increase the risk of dementia
Dr. Mitchell Kling, a psychiatrist at the University of Pennsylvania College of Medicine, University of Pennsylvania, reported that a group of patients with Parkinson's disease Alzheimer's
A total of 304 patients with Alzheimer's Dementia Neuroscience Study, 876 patients with mild cognitive impairment and 186 patients with dementia neuroimaging Alzheimer's disease were included in the study.
At the Memory Center of the University of Pennsylvania, 43 patients with dementia, 18 patients with mild dysfunction and 51 patients with normal mood were also screened for the Rosen Plasma test.
Dr. Kling points out that aging can lead to a higher risk of dementia when the liver's ability to synthesize plasmalogens degrades
The clinical evaluation guidelines published at the conference of the 39, International Alzheimer Association will have a significant impact on national experts in dementia as well as on foreign experts in dementia.
News Dimensia News by Choi Bong-young ([email protected])
Source link
